快到年底了,我们医学领域的几大重要的会议,如AACR、ASCO、WCLC和ESMO都开完了,发现很多粉丝再找这些会议的摘要集(abstract book),小编在此把几大会议的摘要集整理了一下,这样大家可以好好学习这一年的医学进展。医学会议的摘要集获取方法如下: 2023ESMO摘要集(共1163页) 获取方法:关注医微客公众呺,对话框回复关键...
Abstract Book of ESMO Breast Cancer 2024, Berlin, Germany, 15-17 May 2024Publication of this Abstract book is supported by the European Society for Medical Oncology May 2024 Previous vol/issue Next vol/issue Actions for selected articles
1. N. Harbeck, V. Guarneri, J.H. Seo, et al. 93MO Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer (EBC) . ABSTRACT BOOK of the ESMO Breast Cancer, 93MO.2023; 8(1S4):1. ...
Conference abstractOpen access 6P Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis D. Arruda Navarro Albuquerque, M. Trotta Vianna, A. Vasiliu, E.H. Cunha Neves Filho ...
Ortega, et al. HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial. ABSTRACT BOOK of the ESMO Breast Cancer, 3MO.2023; 8(1S4):2...
Access to the Virtual Platform to watch the missed sessions on-demand and Abstract Book Coffee breaks, lunches, welcome cocktail as indicated in the programme Online participation includes: Access to the Virtual Platform, with live streaming of all sessions and possibility to watch the sessions on-...
P. Tolosa Ortega, et al. Patritumab deruxtecan (HER3-DXd) in hormonal receptor positive/ HER2 negative(HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportun...
Publication of this Abstract book is supported by the European Society for Medical Oncology Pages 1202-1274, S215-S1274 (September 2024) Previous vol/issue Next vol/issue Actions for selected articles Select all / Deselect allDownload PDFsExport citations Contents Basic science Biliary tract cancer...
Conference abstractOpen archive 3P Targeting pancreatic adenocarcinoma upregulated factor (PAUF) to treat pancreatic cancer (PC): In vivo efficacy and safety of PBP1510, a first in class monoclonal antibody (mAb) S. Pradhan, Y.J. Kim, J. Park, S-Y. Jeong, ... L. Jaison ...
Ortega, et al. HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial. ABSTRACT BOOK of the ESMO Breast Cancer, 3MO.2023; 8(1S4):2...